ストックスクリーナーアプリを入手
70.84
0.03%
0.02
プレマーケット:
70.84
前日終値:
$70.82
開ける：
$70.9
24時間の取引高:
2.35M
Relative Volume:
0.47
時価総額：
$10.34B
収益：
$10.73M
当期純損益:
$-455.74M
株価収益率:
-19.92
EPS:
-3.5569
ネットキャッシュフロー:
$-502.70M
1週間 パフォーマンス:
+1.52%
1か月 パフォーマンス:
+44.69%
6か月 パフォーマンス:
+137.08%
1年 パフォーマンス:
+34.93%
1日の値動き範囲:
$70.61
$70.95
1週間の範囲:
$69.67
$70.98
52週間の値動き範囲:
$21.51
$72.05
Avidity Biosciences Inc Stock (RNA) Company Profile
名前
Avidity Biosciences Inc
セクター
電話
858-401-7900
住所
3020 CALLAN ROAD, SAN DIEGO, CA
RNA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
70.84 | 10.67B | 10.73M | -455.74M | -502.70M | -3.5569 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.16B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
694.99 | 71.65B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.97 | 59.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.73 | 54.79B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
368.36 | 41.77B | 4.98B | 69.59M | 525.67M | 0.5197 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-17 | 開始されました | Roth Capital | Buy |
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2025-06-24 | 開始されました | Bernstein | Outperform |
| 2025-06-17 | 開始されました | Wolfe Research | Outperform |
| 2025-06-11 | 開始されました | Raymond James | Strong Buy |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2025-03-12 | 開始されました | BMO Capital Markets | Outperform |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-20 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-09-24 | 開始されました | Goldman | Buy |
| 2024-08-28 | 開始されました | Barclays | Overweight |
| 2024-05-03 | 開始されました | BofA Securities | Buy |
| 2024-03-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-05-22 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-03-31 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-07-20 | 開始されました | Chardan Capital Markets | Buy |
| 2022-07-12 | 開始されました | Raymond James | Strong Buy |
| 2021-09-07 | 開始されました | Evercore ISI | Outperform |
| 2021-06-17 | 開始されました | Needham | Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-07-07 | 開始されました | Cowen | Outperform |
| 2020-07-07 | 開始されました | Credit Suisse | Outperform |
| 2020-07-07 | 開始されました | SVB Leerink | Outperform |
| 2020-07-07 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Avidity Biosciences Inc (RNA) 最新ニュース
Price action breakdown for Avidity Biosciences Inc.July 2025 Decliners & Free Daily Entry Point Trade Alerts - newser.com
Detecting support and resistance levels for Avidity Biosciences Inc.Trade Risk Assessment & Free High Return Stock Watch Alerts - newser.com
Visual analytics tools that track Avidity Biosciences Inc. performanceJuly 2025 Setups & Safe Capital Allocation Plans - newser.com
Is Avidity Biosciences Inc. showing signs of accumulationPortfolio Growth Summary & Weekly Breakout Watchlists - newser.com
Will Avidity Biosciences Inc. stock attract more institutional investorsVolume Spike & Technical Pattern Alert System - newser.com
Using AI based signals to follow Avidity Biosciences Inc.July 2025 Analyst Calls & Growth Focused Investment Plans - newser.com
Why Avidity Biosciences Inc. stock is popular among millennialsJuly 2025 Setups & Verified Swing Trading Watchlists - newser.com
What to expect from Avidity Biosciences Inc. in the next 30 daysWatch List & AI Driven Stock Price Forecasts - newser.com
Risk adjusted return profile for Avidity Biosciences Inc. analyzedQuarterly Profit Review & Weekly Breakout Stock Alerts - newser.com
Heatmap analysis for Avidity Biosciences Inc. and competitorsTrade Risk Report & Safe Entry Point Identification - newser.com
Can Avidity Biosciences Inc. stock deliver sustainable ROEJuly 2025 Recap & Free Fast Gain Swing Trade Alerts - newser.com
Short interest data insights for Avidity Biosciences Inc.Jobs Report & Expert Curated Trade Setups - newser.com
Avidity Biosciences stock reaches all-time high at 70.52 USD By Investing.com - Investing.com Nigeria
Why Avidity Biosciences Inc. stock attracts global investorsOptions Play & Technical Pattern Alert System - newser.com
Will Avidity Biosciences Inc. stock deliver long term returns2025 Institutional Moves & Weekly Breakout Stock Alerts - newser.com
Chardan Capital Maintains Avidity Biosciences (RNA) Neutral Recommendation - Nasdaq
Avidity Biosciences stock reaches all-time high at 70.52 USD - Investing.com
Earnings visualization tools for Avidity Biosciences Inc.Quarterly Market Summary & AI Forecast for Swing Trade Picks - newser.com
Should Doubling of Net Losses in Q3 Require Action From Avidity Biosciences (RNA) Investors? - simplywall.st
Applying Wyckoff theory to Avidity Biosciences Inc. stockQuarterly Growth Report & Real-Time Volume Spike Alerts - newser.com
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue Estimates - sharewise.com
Decoding Avidity Biosciences Inc (RNA): A Strategic SWOT Insight - GuruFocus
Avidity Biosciences Reports Increased Revenue Amid Losses - TipRanks
Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights - BioSpace
Key facts: Novartis to merge with Avidity for $12 billion; new plant for cancer therapies - TradingView
Avidity Biosciences Slides On Wider Losses But Keeps Big Plans - Finimize
Avidity Biosciences reports wider-than-expected Q3 net loss - MarketScreener
How Avidity Biosciences Inc. stock compares to growth peersMarket Growth Report & Safe Capital Growth Trade Ideas - newser.com
Is Avidity Biosciences Inc. stock ready for breakoutMarket Movement Recap & Consistent Profit Trade Alerts - newser.com
Avidity Biosciences Inc (RNA) 財務データ
収益
当期純利益
現金流量
EPS
Avidity Biosciences Inc (RNA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Hughes Steven George | Chief Medical Officer |
Oct 22 '25 |
Sale |
47.54 |
2,209 |
105,015 |
38,867 |
| McCarthy Teresa | Chief Human Resources Officer |
Oct 15 '25 |
Option Exercise |
22.34 |
20,000 |
446,800 |
117,130 |
| McCarthy Teresa | Chief Human Resources Officer |
Oct 15 '25 |
Sale |
50.15 |
20,000 |
1,003,058 |
97,130 |
| Mosbrooker Eric | Chief Commercial Officer |
Oct 03 '25 |
Option Exercise |
9.05 |
6,562 |
59,386 |
61,562 |
| Mosbrooker Eric | Chief Commercial Officer |
Oct 03 '25 |
Sale |
45.38 |
6,562 |
297,771 |
55,000 |
| Hughes Steven George | Chief Medical Officer |
Sep 22 '25 |
Option Exercise |
10.16 |
2,208 |
22,433 |
41,075 |
| Hughes Steven George | Chief Medical Officer |
Sep 22 '25 |
Sale |
40.58 |
2,208 |
89,601 |
38,867 |
| McCarthy Teresa | Chief Human Resources Officer |
Sep 15 '25 |
Option Exercise |
22.34 |
15,000 |
335,100 |
112,130 |
| McCarthy Teresa | Chief Human Resources Officer |
Sep 15 '25 |
Sale |
41.41 |
15,000 |
621,142 |
97,130 |
| Hughes Steven George | Chief Medical Officer |
Sep 15 '25 |
Option Exercise |
6.57 |
1,542 |
10,131 |
40,409 |
0.35%
0.75%
大文字化:
|
ボリューム (24 時間):